Á lódáil...
Effectiveness of adjuvant trastuzumab in daily clinical practice
BACKGROUND: Human epidermal growth factor receptor 2 (HER2) positive breast cancer is an entity with aggressive behaviour. One year of adjuvant trastuzumab significantly improves the disease free survival in the range of 40–50% and reduces the risk of dying from HER2 positive breast cancer by one th...
Na minha lista:
| Foilsithe in: | Radiol Oncol |
|---|---|
| Main Authors: | , , |
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe: |
Versita, Warsaw
2014
|
| Ábhair: | |
| Rochtain Ar Líne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4230562/ https://ncbi.nlm.nih.gov/pubmed/25435855 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2478/raon-2013-0081 |
| Clibeanna: |
Cuir Clib Leis
Gan Chlibeanna, Bí ar an gcéad duine leis an taifead seo a chlibeáil!
|